ProShares Bitcoin ETF vs Zoetis Inc — how do they compare? ProShares Bitcoin ETF trades at $8.86, while Zoetis Inc trades at $75.82 (market cap $31.05B). The key difference: Zoetis Inc pays a 2.86% dividend while ProShares Bitcoin ETF pays none. Which is the better fit depends on your goals.
| BITO | ZTS | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $22.93 | $156.76 |
52-Week Low | $7.98 | $71.91 |
Market Cap | — | $31.05B |
Enterprise Value | — | $38.35B |
Dividend Yield | — | 2.86% |
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.44, down 2.65% today amid bearish technical signals with 12 sell indicators versus 4 buy signals. The ETF faces challenges with declining distributions and negative sentiment as crypto markets struggle. Recent dividend payments of $0.01-$0.02 per share provide limited offset to the fund's 24.26% five-year decline.
The outlook remains cautious with structural costs and Bitcoin correlation concerns weighing on performance. Key risks include management fee drag, distribution volatility, and crypto market exposure. Investors should monitor fee structure efficiency and Bitcoin market stability for potential recovery catalysts.
Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.
Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →